Navigation Links
Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma
Date:7/15/2008

NDA or other Cephalon Oncology compounds; interpretation of clinical results, particularly with respect to the TREANDA clinical trials; manufacturing development and capabilities; market prospects for its products; sales and earnings guidance; and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.


'/>"/>
SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology
2. Complete Study Results Comparing CTIs OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology
3. Results Published in the Journal Cancer Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma
4. Journal of Clinical Oncology Publishes Leukine(R) Study Demonstrating Positive Survival Outcomes in Patients with High-Risk Melanoma
5. Journal of Antimicrobial Chemotherapy Paper Supports Additional Role for Cethromycin as Potential Treatment for Infections Caused by Community- Associated Methicillin Resistant Staphylococcus Aureus (CA-MRSA)
6. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
7. The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxters Cell-Based Pandemic, Avian Flu Vaccine
8. Biopure Phase III Orthopedic Trial Results Published in Journal of Trauma
9. New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
10. Blood Spot Technology at ZRT Highlighted in March Issue of Journal of Diabetes Science & Technology - A Convenient Alternative to Serum Testing for Health Screening
11. Anesiva Announces Publication of Phase 3 Zingo(TM) Data in the Journal Pediatrics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation ... focused on discovering, developing and commercializing innovative therapies ... today issued the following open letter to shareholders ... Dr. Med. Sc. Dear RXi Shareholders, ... number of inaccurate statements posted on certain social ...
(Date:12/22/2014)... Calif. , Dec, 22, 2014  Eiger ... Phase 2a study of lonafarnib in patients with ... was conducted at the National Institutes of Health ... .  The double-blinded, randomized, placebo-controlled, dose ascending ... twice daily and 200 mg twice daily for ...
(Date:12/22/2014)... , Dec. 22, 2014  Relmada Therapeutics, Inc. ... for the treatment of chronic pain, announced today ... dosed in a pharmacokinetic and pharmacodynamic study with ... neuropathic pain. Racemic methadone is a ... pain states and substitution therapy in opioid addiction.  ...
Breaking Medicine Technology:RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 2Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 3
... DATATRAK International, Inc. (OTCQX: DATA), a technology and ... clinical trials industry, today announced its attendance at the ... be held in Chicago, Illinois June 19th-23rd. ... #735 on June 20th-22nd. Individuals attending the meeting are ...
... SAN DIEGO, June 10, 2011 Gen-Probe Incorporated (NASDAQ: ... at the William Blair & Company 31st Annual Growth Stock ... p.m. Central Time (5 p.m. Eastern Time).  The presentation is ... a link on the investors section of Gen-Probe,s website at ...
Cached Medicine Technology:DATATRAK Exhibiting at 47th Annual DIA Meeting 2Gen-Probe to Webcast Presentation at the William Blair & Company 31st Annual Growth Stock Conference 2
(Date:12/24/2014)... (HealthDay News) -- Long-term fear of terrorists may damage your ... new study from Israel suggests. , , Conducted by researchers ... Israelis. In Israel, the threat of war and terrorism has ... "We wanted to test whether fear of terrorism can ... death," study author Hermona Soreq, a professor of molecular neuroscience, ...
(Date:12/24/2014)... 2014 (HealthDay News) -- If you are a high-risk ... are not treated by a cardiologist, new research suggests. ... cardiologists left town for annual professional meetings, Harvard researchers ... who were admitted to a teaching hospital during one ... percent died when these meetings were not taking place. ...
(Date:12/22/2014)... As early as thirty, gravity begins to ... form of “jowls." The dreaded droopiness usually appears around ... line or smile lines. Aging can be fought with ... the deep facial tissues descend, jowls inevitably appear. , ... can be used under the skin to fill natural ...
(Date:12/22/2014)... Sagacious Consultants, the premier full-service Epic ... to their ad hoc report writing service to meet ... sign up for an annual subscription and get a ... a deeply discounted hourly rate. , Customers can ... progressively discounted rate. Subscription hours are contracted in 25 ...
(Date:12/22/2014)... York, New York (PRWEB) December 22, 2014 ... are a staple of the season. Many may be thinking ... in a span of a few weeks. Health Republic Insurance ... help of Registered Dietitian, Andrea Chernus, to provide some smart ... eat and stay healthy. , 1)    Avoid arriving at a holiday ...
Breaking Medicine News(10 mins):Health News:Terrorism Fears May Shorten Your Life, Study Finds 2Health News:When Heart Docs Are Away, Their High-Risk Patients May Fare Better 2Health News:When Heart Docs Are Away, Their High-Risk Patients May Fare Better 3Health News:Sam Rizk, MD, FACS, Introduces Rapid Recovery Facelift 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 3Health News:Health Republic Insurance of New York Offers Five Simple Tips to Eat Healthy During the Holidays 2
... of metabolic protein architecture and their advance offers ... ,,Researchers at the University of Illinois ... online edition of the Proceedings of the National Academy ... techniques of phylogenetic analysis developed in the past decade ...
... that it has a mix of properties that would ... matrix with metallic clusters that can absorb light, ... and then destroy those targeted cells with a laser. ... nanocomposite (DNC) matrix containing silver clusters that can be ...
... recently identified genetic marker for prostate cancer is linked ... ,These findings ultimately will aid the development ... susceptible to this aggressive cancer, Northwestern researchers said. Knowing ... doctors in how they treat the cancer. ...
... at Nokia have developed software that transforms a cellphone into ... lightning strike. ,A lightning bolt is an ... frequencies between 10 hertz and five gigahertz. However, the distribution ... is. ,According to the scientists, the multiple receivers ...
... toxic substance, made by certain types of bacteria found in house ... condition eczema or wheezing in children if they are exposed to ... Endotoxin is an element of the cell wall of gram-negative bacteria, ... when the bacteria dies or is damaged. ,The new ...
... The Most Powerful Weight-Loss Formula on Earth!" ... common in many parts of the world and thousands of ... is that there are few regulations to govern this booming ... ones that exist. ,Weight loss is a desperate ...
Cached Medicine News:Health News:Protein Folds Research Offers Insight into Metabolic Evolution 2Health News:Protein Folds Research Offers Insight into Metabolic Evolution 3Health News:Nanocomposite Labeled Cancer Cells Targeted and Destroyed by Using Lasers 2Health News:Genetic Marker Linked to Aggressive Prostate Cancer 2Health News:Beware Weight Loss Drugs, Say Canadian Experts 2Health News:Beware Weight Loss Drugs, Say Canadian Experts 3Health News:Beware Weight Loss Drugs, Say Canadian Experts 4
Cable connections for 5 different adapters: Storz, ACMI, Pentax, Wolf and Olympus....
Lightweight PVC housing for easy transport, integrated handle. Easy lamp exchange....
... in determining functionality of a patient's ... courses of treatment for patients receiving ... and autoimmune dieseases. Kit 030 ... diseases giving rise to high titers ...
Maximum brightness, durability, universal power suply, microprocessor-controlled light output and, in the event of lamp failure or degredation, automatic switchover to an integraged spare lamp....
Medicine Products: